Kaplan Fox Reminds Investors of Microvast Holdings, Inc. (NASDAQ: MVST) to a Securities Class Action Deadline - Contact the Firm Before September 21, 2026

A securities class action alleges Microvast overstated its ability to meet margin targets and complete its Huzhou Phase 3.2 manufacturing expansion by year-end 2025. The complaint cites Microvast's March 16, 2026 disclosure of quarterly gross margin collapsing to about 1% from roughly 36% a year earlier, alongside Q4 revenue of $96.5 million, down 15% year over year. Allegations also follow a June 2025 Grizzly Research report accusing the battery maker of overstating production activity and commercial opportunities; investors have until September 21, 2026 to seek lead-plaintiff status.

Analysis

This is not a new operating disclosure; it is plaintiff-law-firm marketing around alleged historical misstatements. The near-term incremental fundamental impact on MVST should therefore be limited unless the complaint uncovers documents, prompts an SEC inquiry, or management revises prior disclosures. The investable issue is that the allegations reinforce a credibility discount just as the company needs investors to underwrite inventory quality, manufacturing execution, and a return to normalized gross margin; that can constrain equity-financing capacity and raise the cost of capital over the next 6-18 months.

The key second-order risk is working capital. If specialized energy-storage inventory requires further write-downs, cash conversion can deteriorate materially even if reported revenue stabilizes, because future production may require cash investment before legacy stock clears. Customer program delays also create adverse operating leverage: lower plant utilization can prevent margin recovery, making any capacity-expansion narrative value-destructive rather than growth-accretive. Peer battery names with validated OEM-backed demand and stronger balance sheets—such as QS, SLDP, ENVX and FREY—may benefit only marginally; MVST is too small for meaningful industry read-through.

Consensus may overreact to the lawsuit itself, which is commonplace after a major stock decline and has uncertain recovery value. The more useful catalyst path is 1-3 months: audited cash balance, operating-cash-flow trend, inventory reserve movement, utilization commentary, and any evidence that delayed customer ramps convert into binding orders. A sustained recovery would require margin improvement without another inventory charge; absent that, the equity remains an execution-and-liquidity optionality rather than a turnaround investment.

Key Decisions for Investors

• Avoid initiating a directional short solely on this filing: litigation announcements are weak standalone catalysts and MVST's small-cap liquidity/short-interest profile can create sharp squeezes. Reassess after the next earnings release for inventory, cash burn and going-concern language.
• For existing MVST longs, reduce exposure into any lawsuit-driven volatility rally unless management provides independently verifiable evidence of utilization, customer acceptance, and inventory normalization. Thesis invalidation for a bearish stance: two consecutive quarters of gross-margin recovery with no incremental impairment and improving operating cash flow.
• Establish a monitoring trigger rather than a trade: if cash burn accelerates while inventory remains elevated at the next report, consider a 3-6 month MVST short or put position, sized for borrow availability and gap risk. The payoff improves materially if a financing need emerges; risk is a strategic investment, customer award, or asset-sale announcement.
• Do not infer any read-through to BAC; its inclusion is incidental to the law firm's historical credentials and has no identifiable earnings, legal, or balance-sheet linkage.